AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25047046 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75
Study 24717936 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute amphetamine administration following a sensitizing dosage regime
Number of subjects: 0
Study 24717936 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging
Number of subjects: 20
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging without aminophylline
Number of subjects: 20
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg) during CMR stress imaging with aminophylline (125 mg)
Number of subjects: 20
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery facilitated with aminophylline
Number of subjects: 20
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery without aminophylline
Number of subjects: 20
Study 23272658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery with aminophylline
Number of subjects: 20
Study 20669300 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 18
Study 20669300 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 17608869 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (8 sessions over 12 weeks)
Number of subjects: 186
Study 17608869 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 186
Study 17608869 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 186
Study 16258905 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (active drug)
Number of subjects: 125
Study 16258905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 12021741 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 23
Study 12021741 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief massage treatment
Number of subjects: 23
Study 12021741 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 23
Study 10202785 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 month, weekly psychological intervention
Number of subjects: 30
Study 10202785 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend of support and training in coping skills
Number of subjects: 30
Study 10202785 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 30
Study 8651088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alacepril (50 mg)
Number of subjects: 13
Study 8651088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1734740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% amobarbital solution
Number of subjects: 20
Study 1734740 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 20
Study 6381169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV 250 mg intramuscularly and topical b.i.d.
Number of subjects: 60
Study 6381169 — intervention group
Group type: COMPARATOR
Intervention: Neuramide b.i.d. plus other drugs (antibiotics, polivitamins, analgesics, etc.)
Number of subjects: 60
Study 31881993 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-animal interaction (HAI) intervention - volunteering at a local animal shelter
Number of subjects: 70
Study 31881993 — intervention group
Group type: COMPARATOR
Intervention: Community volunteer condition - volunteering at a community agency of their choice
Number of subjects: 70
Study 29676689 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1000 mg/100 ml every 8 hours for 48 hours
Number of subjects: 204
Study 29676689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml of 0.9% normal saline every 8 hours for 48 hours)
Number of subjects: 204
Study 29676689 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 204
Study 29676689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 26930415 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) with Xpert MTB/RIF
Number of subjects: 0
Study 26930415 — intervention group
Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 0
Study 22998596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume local anesthesia (≥7.2 mL, four carpules)
Number of subjects: 100
Study 22998596 — intervention group
Group type: COMPARATOR
Intervention: Low-volume local anesthesia (≤0.9 mL, half a carpule)
Number of subjects: 100
Study 22287203 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised therapy
Number of subjects: 22
Study 22287203 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled exercise therapy
Number of subjects: 22
Study 20375404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine
Number of subjects: 410
Study 20375404 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 410
Study 17391294 — intervention group
Group type: COMPARATOR
Intervention: ICF modified by a working group (C)
Number of subjects: 0
Study 17391294 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF with systematic lexico‐syntactic readability improvement (B)
Number of subjects: 0
Study 17391294 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF modified by the working group followed by systematic lexico‐syntactic improvement (D)
Number of subjects: 0
Study 15764686 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-novella (Laduma)
Number of subjects: 1168
Study 12040953 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg orally twice daily for 2 days
Number of subjects: 1005
Study 12040953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 100 mg orally twice daily for 2 days
Number of subjects: 1005
Study 12040953 — intervention group
Group type: COMPARATOR
Intervention: BV-negative group (no treatment)
Number of subjects: 1005
Study 9462527 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% humidified oxygen
Number of subjects: 40
Study 9462527 — intervention group
Group type: COMPARATOR
Intervention: Medical compressed air (room air)
Number of subjects: 40
Study 8527349 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK (100-200 mg once daily)
Number of subjects: 24
Study 8527349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 24
Study 1615139 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa medication
Number of subjects: 10
Study 1615139 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of L-dopa medication
Number of subjects: 10
Study 6700850 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (two-dose perioperative course)
Number of subjects: 150
Study 6700850 — intervention group
Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 150
Study 31211324 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin pre-treatment
Number of subjects: 6800
Study 31211324 — intervention group
Group type: COMPARATOR
Intervention: Placebo during trial
Number of subjects: 6800
Study 31211324 — intervention group
Group type: COMPARATOR
Intervention: Randomized comparison (not specified intervention)
Number of subjects: 6800
Study 29538220 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine warm compress (CMWC) combined with WHO 3-step analgesic ladder treatment
Number of subjects: 62
Study 29538220 — intervention group
Group type: COMPARATOR
Intervention: WHO 3-step analgesic ladder treatment (control group)
Number of subjects: 62
Study 27548072 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 6 weeks
Number of subjects: 89
Study 27548072 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) as add-on therapy
Number of subjects: 89
Study 27548072 — intervention group
Group type: COMPARATOR
Intervention: No CPAP (control group)
Number of subjects: 89
Study 24905241 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based Cognitive Behaviour Therapy (CBT)
Number of subjects: 5030
Study 22279190 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle synergies (4 synergies used)
Number of subjects: 8
Study 22279190 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle synergies
Number of subjects: 8
Study 21046929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 403
Study 17416261 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir-ritonavir 600/100 mg twice daily
Number of subjects: 230
Study 17416261 — intervention group
Group type: COMPARATOR
Intervention: Control PIs
Number of subjects: 230
Study 15702343 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming with fins
Number of subjects: 0
Study 15702343 — intervention group
Group type: COMPARATOR
Intervention: Swimming without fins
Number of subjects: 0
Study 12162977 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 24
Study 12162977 — intervention group
Group type: COMPARATOR
Intervention: Upper arm tourniquet
Number of subjects: 24
Study 10212733 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 38
Study 10212733 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 38
Study 7619619 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 4.5 mg I/ml
Number of subjects: 0
Study 7619619 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 6.75 mg I/ml
Number of subjects: 0
Study 7619619 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol 9 mg I/ml
Number of subjects: 0
Study 2617277 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 7
Study 2617277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1273032 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampicillin hydrochloride (125 mg of ampicillin equivalent, four times daily for six days)
Number of subjects: 0
Study 1273032 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (250 mg, four times daily for six days)
Number of subjects: 0
Study 1273032 — intervention group
Group type: EXPERIMENTAL
Intervention: Talampicillin
Number of subjects: 0
Study 1273032 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive (LARC) methods
Number of subjects: 2551
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable contraceptives
Number of subjects: 2551
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device
Number of subjects: 2551
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraceptives (depot medroxyprogesterone acetate)
Number of subjects: 2551
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraceptives (norethisterone enanthate)
Number of subjects: 2551
Study 31226323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 2551
Study 29076668 — intervention group
Group type: EXPERIMENTAL
Intervention: 6mg dexamethasone in 4 doses 12 hours apart (Group A)
Number of subjects: 48
Study 29076668 — intervention group
Group type: COMPARATOR
Intervention: 2 doses 12 hours apart (Group B)
Number of subjects: 48
Study 29076668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens of dexamethasone
Number of subjects: 48
Study 25741915 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam administered three times by weekly intervals
Number of subjects: 40
Study 25741915 — intervention group
Group type: COMPARATOR
Intervention: 40 mg methylprednisolone acetate administered just once
Number of subjects: 40
Study 23907544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective-memory task with sustained activity in attentional-control areas (anterior prefrontal cortex)
Number of subjects: 0
Study 23907544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective-memory task with transient activity in parietal and ventral brain regions
Number of subjects: 0
Study 21459214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + prompt laser
Number of subjects: 691
Study 21459214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab + deferred laser
Number of subjects: 691
Study 21459214 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone + prompt laser
Number of subjects: 691
Study 21459214 — intervention group
Group type: COMPARATOR
Intervention: Sham + prompt laser
Number of subjects: 691
Study 21459214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab groups
Number of subjects: 691
Study 19238125 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 0
Study 19238125 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-norepinephrine reuptake inhibitor (SNRI)
Number of subjects: 0
Study 19238125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19238125 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation treatment
Number of subjects: 0
Study 16931634 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow monitoring
Number of subjects: 296
Study 16931634 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring
Number of subjects: 296
Study 16931634 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow monitoring (twice daily or as needed)
Number of subjects: 296
Study 16931634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 296
Study 15324523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations b.i.d. if asthma worsened)
Number of subjects: 4025
Study 15324523 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing (budesonide/formoterol 2 inhalations b.i.d.)
Number of subjects: 4025
Study 11765145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 11
Study 11765145 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study 9246030 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler group
Number of subjects: 100
Study 9246030 — intervention group
Group type: COMPARATOR
Intervention: Forrest group
Number of subjects: 100
Study 8317785 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms/puff, 2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0
Study 8317785 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (250 micrograms/puff, 2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0
Study 8317785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs b.i.d. and 4 puffs b.i.d.)
Number of subjects: 0
Study 3015543 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential intermittent polychemotherapy (sq.CT) of 3 different alternating drug combinations given intermittently over 1 year
Number of subjects: 52
Study 3015543 — intervention group
Group type: COMPARATOR
Intervention: 4-drug combination chemotherapy (CT) given intermittently over 3 years
Number of subjects: 52
Study 31486624 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes, followed by Ringer's lactate until the end of surgery (Group P)
Number of subjects: 93
Study 31486624 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate of Ringer's lactate preoperatively for 30 minutes and 5% Dextrose during the operation (Group I)
Number of subjects: 93
Study 31486624 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution infusion at a rate of 10 mL/kg/h (Group C)
Number of subjects: 93
Study 31486624 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes (Group P)
Number of subjects: 93
Study 29723608 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 680
Study 29723608 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 680
Study 29723608 — intervention group
Group type: EXPERIMENTAL
Intervention: Osborn waves presence
Number of subjects: 680
Study 26779845 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH
Number of subjects: 237
Study 26779845 — intervention group
Group type: COMPARATOR
Intervention: ATX
Number of subjects: 237
Study 25342703 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 12
Study 25342703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25342703 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and time-on-task
Number of subjects: 12
Study 25342703 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 25342703 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-on-task
Number of subjects: 12
Study 23545346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg spinal morphine
Number of subjects: 40
Study 23545346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg spinal morphine
Number of subjects: 40
Study 19636702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (100 mg/m(2)) followed by epirubicin (75 mg/m(2)) plus cyclophosphamide (700 mg/m(2))
Number of subjects: 756
Study 19636702 — intervention group
Group type: COMPARATOR
Intervention: FEC regimen (epirubicin 75 mg/m(2), cyclophosphamide 700 mg/m(2), and 5-fluorouracil 700 mg/m(2))
Number of subjects: 756
Study 19636702 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 756
Study 19636702 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia requiring administration of granulocyte colony-stimulating factor
Number of subjects: 756
Study 18363076 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered, computer-tailored lifestyle intervention targeting saturated fat intake
Number of subjects: 0
Study 18363076 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered, computer-tailored lifestyle intervention targeting physical activity
Number of subjects: 0
Study 18363076 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waiting list control group)
Number of subjects: 0
Study 15963377 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal task (newly designed, no manual responses)
Number of subjects: 0
Study 15963377 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual task (similar to conventional line bisection tasks)
Number of subjects: 0
Study 15963377 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12558203 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 480
Study 12558203 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed video
Number of subjects: 480
Study 10587287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 15 mg/day
Number of subjects: 16
Study 10587287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8732386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 ml.kg‐1 Albunex
Number of subjects: 0
Study 8732386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.22 ml.kg‐1 Albunex
Number of subjects: 0
Study 8732386 — intervention group
Group type: COMPARATOR
Intervention: 10 ml albumin
Number of subjects: 0
Study 1816592 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervals of 1-3 seconds
Number of subjects: 0
Study 1816592 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervals of 4 seconds or longer
Number of subjects: 0
Study 1816592 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter reproduction intervals (1-3 seconds)
Number of subjects: 0
Study 1816592 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer reproduction intervals (4 seconds or longer)
Number of subjects: 0
Study 6315259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol (160 mg daily) and verapamil (360 mg daily)
Number of subjects: 18
Study 6315259 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg daily)
Number of subjects: 18
Study 6315259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6315259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol and verapamil
Number of subjects: 18
Study 6315259 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 18
Study 30444145 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tapentadol
Number of subjects: 68
Study 30444145 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 68
Study 30444145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 68
Study 29262811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen program (3-hour weekly classes for 6 weeks, including hands-on cooking and a market tour)
Number of subjects: 80
Study 29262811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen program
Number of subjects: 80
Study 29262811 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 80
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 4%/kg feed
Number of subjects: 0
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 0.5%/kg feed
Number of subjects: 0
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 2%/kg feed
Number of subjects: 0
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera at 1%/kg feed
Number of subjects: 0
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera (various dosages)
Number of subjects: 0
Study 26109009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Aloe vera (less than or equal to 1.88, 1.86, and 2.79%/kg feed)
Number of subjects: 0
Study 23681836 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (MI) 100 mg intravenously for 4 days
Number of subjects: 18